The short version of synthetic peptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-08. Anything still debated is marked as such rather than presented as settled.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
* Disputed ** Separated to Maroodi Jeex and Sahil by Somaliland *** Shared by Puntland and Galmudug Northern Somalia is now de facto divided up among the autonomous regions of Puntland (which considers itself an autonomous state), Somaliland (a self-declared, partially-recognised state) and newly established North East State of Somalia. In central Somalia, Galmudug is another regional entity that emerged just south of Puntland. Jubaland in the far south is a fourth autonomous region within the federation. In 2014, a new South West State was likewise established. In April 2015, a formation conference was also launched for a new Hirshabelle State. The Federal Parliament was tasked in 2012 with selecting the ultimate number and boundaries of the autonomous regional states (officially Federal Member States) within the Federal Republic of Somalia.
Classifying Datura as to its species is difficult, and the descriptions of new species often are accepted prematurely. Later, these "new species" are found to be simply varieties that have evolved due to conditions at a specific location. These new designations usually disappear in a few years. Contributing to the confusion is the fact that various species, such as D. wrightii and D. innoxia, are very similar in appearance, and the variation within a species can be extreme. For example, Datura species can change size of plant, leaf and flowers, all depending on location. The same species, when growing in a half-shady, damp location, can develop into a flowering bush 80 cm (30 in) in height, but when growing in a very dry location, will only grow into a thin plant not much more 13 cm (5 in), with tiny flowers and a few miniature leaves. Datura species are native to dry, temperate and subtropical regions. Most species are native to Mexico, which is considered the centre of origin of the genus. Several species are considered to have extra-American native ranges: D. ferox (native to China), D. metel (native to India and Southeast Asia) and D. leichardthii (native to Australia); however, these may be early introductions from Central America.
The two main types of dialysis, hemodialysis and peritoneal dialysis, remove wastes and excess water from the blood in different ways. Hemodialysis removes wastes and water by circulating blood outside the body through an external filter, called a dialyzer, that contains a semipermeable membrane. The blood flows in one direction and the dialysate flows in the opposite. The counter-current flow of the blood and dialysate maximizes the concentration gradient of solutes between the blood and dialysate, which helps to remove more urea and creatinine from the blood. The concentrations of solutes normally found in the urine (for example potassium, phosphorus and urea) are undesirably high in the blood, but low or absent in the dialysis solution, and constant replacement of the dialysate ensures that the concentration of undesired solutes is kept low on this side of the membrane. The dialysis solution has levels of minerals like potassium and calcium that are similar to their natural concentration in healthy blood. For another solute, bicarbonate, dialysis solution level is set at a slightly higher level than in normal blood, to encourage the diffusion of bicarbonate into the blood, to act as a pH buffer to neutralize the metabolic acidosis that is often present in these patients. The levels of the components of dialysate are typically prescribed by a nephrologist according to the needs of the individual patient. In peritoneal dialysis, wastes and water are removed from the blood inside the body using the peritoneum as a natural semipermeable membrane.
Taruc and others claimed that civilian guards and government officials were "sabotaging the peace process". On August 24, 1946, Feleo was stopped by a large band of "armed men in fatigue uniforms" in Gapan, Nueva Ecija. He had planned to present the peasant's concerns to the Secretary of the Interior Jose Zulueta, before he was taken and killed. Thousands of Huk veterans and PKM members were sure that Feleo was murdered by landlords, or possibly the Roxas administration itself. The incident led to Taruc joining the peasants and re-igniting the insurrection. The Roxas administration then outlawed the Hukbalahap on March 6, 1948. In 1949, Hukbalahap members ambushed and murdered Aurora Quezon, Chairman of the Philippine Red Cross and widow of the Philippines' second president, Manuel L. Quezon, as she was en route to her hometown for the dedication of the Quezon Memorial Hospital. Several others were also killed, including her eldest daughter and son-in-law. This attack brought worldwide condemnation of the Huks, who claimed that the attack was done by "renegade" members. The continuing condemnation and new post-war causes of the movement prompted the Huk leaders to adopt a new name, the "Hukbong Mapagpalaya ng Bayan" or the "People's Liberation Army" in 1950. Public sympathies for the movement had been waning due to their postwar attacks. The Huks confiscated funds and property to sustain their movement and relied on small village organizers for political and material support.
=== Ligand selanoproteins === Besides the selenocysteine-containing selenoproteins, there are also some selenoproteins known from bacterial species, which have selenium bound noncovalently. Most of these proteins are thought to contain a selenide-ligand to a molybdopterin cofactor at their active sites (e.g. nicotinate dehydrogenase of Eubacterium barkeri, or xanthine dehydrogenases).
Sources: en.wikipedia.org
The Convention on Psychotropic Substances was adopted in 1971, entered into force on August 16, 1976, has been joined by 184 countries. It addresses a number of synthetic psychotropic substances, such as amphetamines, barbiturates, and LSD, that had become widely used since World War II, and especially in the 1960s, and were generally not regulated internationally. According to the UNODC, the convention "responded to the diversification and expansion of the spectrum of drugs of abuse and introduced controls over a number of synthetic drugs according to their abuse potential on the one hand and their therapeutic value on the other". The convention classifies the drugs it concerns in a four-schedule system different in the details from the Single Convention schedules.
== PDI-PIXE-MS == Particle desorption ionisation particle-induced X-ray emission mass spectrometry (PIXE-MS) is a technique which combines PIXE with mass spectrometry of molecules. Elemental determinations are performed by PIXE with a heavy ion, such as oxygen, while simultaneously collecting the molecular ions for mass analysis in a quadrupole mass spectrometer, or time-of-flight (TOF) instrument. ICP-MS only determines elemental constituents using mass spectrometry, not molecular information. Sequential scanning may be done with a hydrogen ion beam and then a heavy ion beam to desorb and ionise the analyte sample. This technique allows for the analysis of both the elemental constituents as well as the molecular ions, or molecular speciation, present in a sample, using a heavy ion beam. This makes use, typically, of a 4 MeV accelerator with samples prepared in glycerol, on carbon felt.
Jupiter Wagons Limited is an Indian private manufacturer of railway freight wagons, passenger coaches, wagon components, cast manganese steel crossings and castings headquartered in Kolkata, West Bengal. The company manufactures coaches for the Indian Railways and many other private companies.
In the last 50 years, fashion in India has changed a great deal. In urban northern India, the sari is increasingly no longer everyday wear, though it remains popular on formal occasions. Younger urban women rarely wear the traditional shalwar kameez, favouring churidars or jeans. In office settings, ubiquitous air conditioning allows men to wear sports jackets year-round. For weddings and formal occasions, men in the middle and upper classes often wear bandhgala, or short Nehru jackets, with pants, with the groom and his groomsmen sporting sherwanis and churidars.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.